Search Results | MSF Science Portal

Science Portal

v2.1.5662.produseast1

About MSF Science Portal

About

Frequently Asked Questions (FAQs)

v2.1.5662.produseast1

Showing 1 - 20 of 428 Items

Sort By: Newest to Oldest

Newest to oldest
Oldest to newest
Relevance

Journal Article

Research

Dolutegravir resistance in Mozambique: Insights from a programmatic HIV resistance testing intervention in a highly antiretroviral therapy-experienced cohort

Ruano M, Flores A, Couto A, Gaspar I, Yerly S, et al.

2025-09-30 • Infectious Disease Reports

BACKGROUNDS

Treatment failure continues to play a role in HIV-related morbidity in Mozambique. Antiretroviral therapy (ART) regimen switches are decided empiric...

Journal Article

Pre-Print

Journal Article

Research

Journal Article

Commentary

Journal Article

Commentary

Journal Article

Research

Journal Article

Research

Journal Article

Research

Journal Article

Review

Journal Article

Research

Journal Article

Review

Journal Article

Commentary

Journal Article

Commentary

Journal Article

Research

Journal Article

Research

Journal Article

Review

Journal Article

Research

Journal Article

Review

Journal Article

Letter

Journal Article

Research

Journal Article

Pre-Print

Journal Article

Research

Journal Article

Commentary

Journal Article

Commentary

Journal Article

Research

Journal Article

Research

Journal Article

Research

Journal Article

Review

Journal Article

Research

Journal Article

Review

Journal Article

Commentary

Journal Article

Commentary

Journal Article

Research

Journal Article

Research

Journal Article

Review

Journal Article

Research

Journal Article

Review

Journal Article

Letter

Journal Article

Research

Effect of smoking on drug-resistant tuberculosis treatment outcomes and exploring potential pathways: A multicountry cohort study

Romo ML, LaHood A, Stagg HR, Mitnick CD, Trevisi L, et al.

2025-08-24 • medRxiv

People who smoke are at increased risk of unfavorable tuberculosis (TB) treatment outcomes compared with tho...

Characterizing treatment adherence trajectories in the endTB multisite cohort of drug-resistant tuberculosis patients: an application of group-based trajectory modelling

Law S, Fulcher I, Ashraf S, Bastard M, Docteur W, et al.

2025-08-22 • Clinical Infectious Diseases

BACKGROUND

In tuberculosis (TB) care, adherence is often assessed using a simple 80% threshold, ...

A strategic approach to regulating new antimicrobials

Malhotra S, Bansal N, Ramasubramanian V, Balaji V, Menghaney L, et al.

2025-08-18 • Journal of Global Health

Antimicrobial resistance (AMR) is a significant threat to healthcare in India, which is experiencing increasing&n...

Advancing clinical bacteriology in humanitarian settings: The collaborative role of Médecins Sans Frontières

Garcia-Vello P, Doyle D, Vollmer S, Baidjoe A, Kanapathipillai R, et al.

2025-08-16 • Journal of Global Antimicrobial Resistance

Antimicrobial resistance (AMR) is a growing global health threat, particularly in resource-limited and conflict-affect...

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant/rifampicin-resistant tuberculosis cohort

Khan U, Rich M, Franke MF, Lachenal N, Ahmed S, et al.

2025-08-01 • Clinical Infectious Diseases

BACKGROUND

The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...

Acquisition of Escherichia coli carrying extended-spectrum ß-lactamase and carbapenemase genes by hospitalised children with severe acute malnutrition in Niger

Sands K, Lankapalli AK, Lai G, Hassan B, Portal EA, et al.

2025-08-01 • Nature Communications

Hospitalisation and routine antibiotic treatment are recommended for children with complicated severe acute...

Performance evaluation of the Mini-Lab, an all-in-one clinical bacteriology laboratory adapted to low-resource settings, in a district hospital in Central African Republic: a prospective descriptive study

Langendorf C, Ronat JB, Natale A, Vidal T, Kodo H, et al.

2025-07-29 • International Journal of Infectious Diseases

BACKGROUND

Médecins sans Frontières designed an all-in-one microbiology laboratory (the "Mini-Lab") to improve bacterial infections diagnosis in low-r...

Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: An individual patient data meta-analysis

Kwak N, Kim JY, Han A, Berry C, Beumont M, et al.

2025-07-17 • European Respiratory Journal

BACKGROUND

The optimal dosing strategy of linezolid for treating multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) remains unclear. We condu...

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, et al.

2025-07-16 • Lancet Respiratory Medicine

Clinical best practices for caring for people with expanded resistance to newer TB drugs

Nkomo T, Udwadia Z, Vambe D, van Rie A, Thi S, et al.

2025-06-13 • IJTLD OPEN

BACKGROUND

Strains of Mycobacterium tuberculosis

Keeping our feet on the ground: the role of innovation in scaling up diagnosis to counter antimicrobial resistance

Alkon A, Cunningham J, Kanapathipillai R, Naim C, Shortall C, et al.

2025-05-01 • Lancet Microbe

Unravelling the linkages between conflict and antimicrobial resistance

Abbara A, Shortall C, Sullivan R, Zwijnenburg W, Moussally K, et al.

2025-04-12 • NPJ Antimicrobials and Resistance

Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia

Ardizzoni E, Mulders W, De Diego Fuertes M, Hayrapetyan A, Mirzoyan A, et al.

2025-04-09 • Antimicrobial Agents and Chemotherapy

Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenia...

Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: A multicentric retrospective cohort study

Singla R, Khan S, Silsarma A, Chavan V, Mahajan R, et al.

2025-03-13 • Clinical Infectious Diseases

BACKGROUND

Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. Th...

Improving equitable access for effective antibacterial: An ecosystem approach

Cohn J, Balasegaram M, Srinivasan H, Menghaney L, Mpundu M, et al.

2025-03-01 • Clinical Microbiology and Infection

BACKGROUND

Antibiotics are indispensable to modern healthcare, yet their equitable access remains a pressing global challenge. Factors contributing to inequitie...

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, et al.

2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Conflict-associated wounds and burns infected with GLASS pathogens in the Eastern Mediterranean Region: A systematic review

Wild A, Shortall C, Dewachi O, Naim C, Green A, et al.

2025-02-07 • BMC Infectious Diseases

BACKGROUND

While the relationship between conflict-associated injuries and antimicrobial resistance is increasingly being elucidated, data concerning civilian c...

Sustained treatment success at 12 months for drug-resistant TB patients on concomitant bedaquiline-delamanid

Chavan V, Silsarma A, Mahajan R, Khan S, Singh P, et al.

2025-02-01 • IJTLD OPEN

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, et al.

2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...